Lisata Therapeutics’ (LSTA) Hold Rating Reiterated at Brookline Capital Management

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “hold” rating reissued by research analysts at Brookline Capital Management in a research report issued on Wednesday,Benzinga reports.

Other equities analysts have also issued reports about the stock. Zacks Research lowered shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Trading Up 86.8%

LSTA traded up $1.88 during mid-day trading on Wednesday, hitting $4.04. 4,129,794 shares of the stock were exchanged, compared to its average volume of 352,753. The company has a market cap of $35.59 million, a PE ratio of -1.89 and a beta of 1.11. The firm’s fifty day moving average is $2.03 and its two-hundred day moving average is $2.32. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $4.04.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.05. As a group, research analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics during the 2nd quarter valued at approximately $32,000. CIBC Bancorp USA Inc. bought a new stake in shares of Lisata Therapeutics during the 3rd quarter valued at about $37,000. Finally, Ground Swell Capital LLC bought a new stake in shares of Lisata Therapeutics in the 3rd quarter worth approximately $62,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.